Fantastic coverage of this approval. The testing disparity here is staggering, 23 men versus 2 women for a drug targeting female sexual desire basically encapsulates decades of pharma prioritizing speed and convenience over appropriate cohort selection. I've seen similar patterns in cardiovascular trials where womens' symptom profiles differ substantially but get lumped into male-dominated datasets. The fact it took a decade plus Canada's earlier move to expand this indicaton says alot about how regulatory frameworks lag behind clinical need.
Fantastic coverage of this approval. The testing disparity here is staggering, 23 men versus 2 women for a drug targeting female sexual desire basically encapsulates decades of pharma prioritizing speed and convenience over appropriate cohort selection. I've seen similar patterns in cardiovascular trials where womens' symptom profiles differ substantially but get lumped into male-dominated datasets. The fact it took a decade plus Canada's earlier move to expand this indicaton says alot about how regulatory frameworks lag behind clinical need.
Absolutely - and let's hope this is a sign of more positive regulatory focus on unmet needs.